CD274 and neoplasm: Combining macitentan with an anti-PD-L1 antibody improved anti-tumor efficacy by increasing the CD8+ T cell number and activity, accompanied by fewer Tregs in the tumors and draining lymph nodes of triple-negative breast cancer, colon and lung syngeneic tumor models.